PDCD1 and neoplasm: However, when this was combined with antibodies directed against the CD8+ T cell inhibitory receptors PD-1 and CTLA-4 as well as the inhibitory ligand PD-L1 we were able to obtain long-lasting protection from the B16-OVA tumor in 70% of C57BL/6 mice.